Hyunseok Kang

26PUBLICATIONS
76CO-AUTHORS
Predictive and prognostic markersBiologically active moleculesMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (26)

|Sep 09, 2026
Statin Use Is Associated With Progression-Free Survival for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Treated With Pembrolizumab.

|Aug 03, 2026
A Selective CK1α Degrader Targets Acute Myeloid Leukemia and Spares Normal Hematopoietic Cells.

|Jun 18, 2026
Metastatic Lymph Node Status Is Associated With Progression-Free Survival in Oral Cavity Squamous Cell Carcinoma Treated With Pembrolizumab.

|May 25, 2026
Potent Anti-Tumor Activity of the AXL-Targeted Antibody-Drug Conjugate, Mipasetamab Uzoptirine (ADCT-601), in Preclinical Models of Adenoid Cystic Carcinoma.

|May 10, 2026
Neutrophil-To-Lymphocyte Ratio and Survival in Pembrolizumab-Treated Oropharyngeal Cancer.

|May 05, 2026
Potent anti-tumor activity of the AXL-targeted antibody-drug conjugate, mipasetamab uzoptirine (ADCT-601), in preclinical models of adenoid cystic carcinoma.

Pageof 5

Frequent Collaborators

6 joint publications

Patrick K Ha

6 joint publications

Rex H Lee

4 joint publications

Ivan H El-Sayed

4 joint publications

Chase M Heaton